Joost Oppenheim

Senior Investigator


Joost Oppenheim

Dr. Oppenheim pioneered the development of cytokine, chemokine and alarmin fields of research. He is currently studying the role of alarmins that activate toll-like receptors, in inducing immunity to cancer. He has been engaged in translational studies aimed at utilizing alarmins as adjuvants in vaccines for use against infectious agents and tumors. He is also investigating means of blocking the immunosuppressive limb of immunity as exerted by T regulatory cells to augment antitumor immunity. Dr. Oppenheim is the Chief of the Laboratory of Molecular Immunoregulation and the Deputy Director of the Cancer and Inflammation Program at the National Cancer Institute which focuses on the effects of inflammation and the immune response on cancer.

Follow Joost Oppenheim' at upcoming/ongoing conferences at gtcbio:

Cancer Immunotherapy & Immunomonitoring

Immunotherapeutics & Immunomonitoring 2018